[go: up one dir, main page]

PE20120058A1 - Derivados de imidazopirazina como inhibidores de syk - Google Patents

Derivados de imidazopirazina como inhibidores de syk

Info

Publication number
PE20120058A1
PE20120058A1 PE2011001178A PE2011001178A PE20120058A1 PE 20120058 A1 PE20120058 A1 PE 20120058A1 PE 2011001178 A PE2011001178 A PE 2011001178A PE 2011001178 A PE2011001178 A PE 2011001178A PE 20120058 A1 PE20120058 A1 PE 20120058A1
Authority
PE
Peru
Prior art keywords
hydrogen
imidazopyrazine
syk inhibitors
halogen
alkyl
Prior art date
Application number
PE2011001178A
Other languages
English (en)
Inventor
Scott A Mitchell
Peter A Blomgren
Jeffrey E Kropf
Seung H Lee
Jianjun Xu
Douglas G Stafford
James P Harding
Zhongdong Zhao
Jr Antonio J Barbosa
Kevin S Currie
David M Armistead
Original Assignee
Gilead Connecticut Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120058(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Connecticut Inc filed Critical Gilead Connecticut Inc
Publication of PE20120058A1 publication Critical patent/PE20120058A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE IMIDAZOPIRAZINA DE FORMULA (I), DONDE R1 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXILO, CARBOXILO, CIANO, ENTRE OTROS; R2 ES ARILO DE 5 O 6 MIEMBROS TAL COMO BENCENO O HETEROARILO DE 5 A 7 MIEMBROS, ENTRE OTROS; R3 ES HIDROGENO, ALQUILO C1-C4, HALOGENO; R4 ES HIDROGENO O ALQUILO C1-C4; R5 ES HIDROGENO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA TIROSINA QUINASA DEL BAZO (SYK) Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS ALERGICOS, ENFERMEDADES AUTOINMUNITARIAS, ENFERMEDADES INFLAMATORIAS, ENTRE OTRAS
PE2011001178A 2008-12-08 2009-12-07 Derivados de imidazopirazina como inhibidores de syk PE20120058A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12058708P 2008-12-08 2008-12-08
US14051408P 2008-12-23 2008-12-23
US24097909P 2009-09-09 2009-09-09

Publications (1)

Publication Number Publication Date
PE20120058A1 true PE20120058A1 (es) 2012-02-02

Family

ID=42242994

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014000121A PE20140975A1 (es) 2008-12-08 2009-12-07 Derivados de imidazopirazina como inhibidores de syk
PE2011001178A PE20120058A1 (es) 2008-12-08 2009-12-07 Derivados de imidazopirazina como inhibidores de syk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014000121A PE20140975A1 (es) 2008-12-08 2009-12-07 Derivados de imidazopirazina como inhibidores de syk

Country Status (30)

Country Link
US (7) US8455493B2 (es)
EP (3) EP3123864A1 (es)
JP (4) JP5567587B2 (es)
KR (4) KR101745732B1 (es)
CN (2) CN102307474B (es)
AU (1) AU2009325132B2 (es)
BR (1) BRPI0922225B1 (es)
CA (1) CA2746023C (es)
CL (1) CL2011001360A1 (es)
CO (1) CO6390078A2 (es)
CY (1) CY1118377T1 (es)
DK (1) DK2716157T3 (es)
EA (3) EA024140B1 (es)
ES (2) ES2545610T3 (es)
HR (1) HRP20161036T1 (es)
HU (1) HUE030427T2 (es)
IL (3) IL213365A (es)
LT (1) LT2716157T (es)
MX (1) MX2011006091A (es)
NZ (1) NZ593459A (es)
PE (2) PE20140975A1 (es)
PL (2) PL2716157T3 (es)
PT (2) PT2716157T (es)
RS (1) RS55055B1 (es)
SG (1) SG171991A1 (es)
SI (2) SI2716157T1 (es)
SM (1) SMT201600267B (es)
TW (2) TWI478922B (es)
VN (1) VN28228A1 (es)
WO (1) WO2010068257A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102468A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
AU2009325133B2 (en) 2008-12-08 2016-02-04 Gilead Connecticut, Inc. Imidazopyrazine Syk inhibitors
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
KR101745732B1 (ko) 2008-12-08 2017-06-12 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
AU2010284254B2 (en) * 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
US9290490B2 (en) 2011-05-10 2016-03-22 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013052393A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
WO2013188856A1 (en) * 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
JP2015529195A (ja) * 2012-08-14 2015-10-05 ギリアード カリストガ エルエルシー 癌を処置するための組合せ治療
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015017466A1 (en) * 2013-07-30 2015-02-05 Gilead Connecticut, Inc. Formulation of syk inhibitors
WO2015017460A1 (en) * 2013-07-30 2015-02-05 Gilead Connecticut, Inc. Polymorph of syk inhibitors
JP6159028B2 (ja) 2013-07-31 2017-07-05 ギリアード サイエンシーズ， インコーポレイテッド Ｓｙｋ阻害剤
JP6298539B2 (ja) 2013-12-04 2018-03-20 ギリアード サイエンシーズ， インコーポレイテッド がんを処置する方法
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
EP3152214B1 (en) * 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
TW201617074A (zh) * 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
EA201790086A1 (ru) 2014-07-14 2017-07-31 Джилид Сайэнс, Инк. Комбинации для лечения раковых заболеваний
TW201639573A (zh) * 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
KR20170137200A (ko) * 2015-04-21 2017-12-12 길리애드 사이언시즈, 인코포레이티드 Syk 억제제를 사용한 만성 이식편 대 숙주 질환의 치료
US20180201614A1 (en) * 2015-05-12 2018-07-19 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
WO2016197987A1 (zh) * 2015-06-12 2016-12-15 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
WO2017106564A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
US20190160035A1 (en) * 2016-07-28 2019-05-30 Qbiotics Limited Method of treatment
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
US10111882B2 (en) 2016-09-14 2018-10-30 Gilead Sciences, Inc. SYK inhibitors
US11142535B2 (en) * 2016-12-12 2021-10-12 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
JP2020531574A (ja) * 2017-08-18 2020-11-05 北京韓美薬品有限公司Ｂｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍ． Ｃｏ．， Ｌｔｄ． 化合物、その医薬組成物及びその使用及び応用
CN111051311A (zh) 2017-08-25 2020-04-21 吉利德科学公司 Syk抑制剂的多晶型物
AU2018350683A1 (en) 2017-10-19 2020-04-02 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
CN109879878A (zh) * 2017-12-06 2019-06-14 朱允涛 一种氘代的咪唑并吡嗪类脾酪氨酸激酶（Syk）抑制剂
US12012394B2 (en) 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP7535600B2 (ja) * 2020-06-01 2024-08-16 ナンジン ルイジエ ファーマ シーオー．，エルティーディー． 化合物および脾臓チロシンキナーゼ阻害剤としてのその使用
JP2023542724A (ja) 2020-09-28 2023-10-11 ファースト・バイオセラピューティクス・インコーポレイテッド 造血前駆細胞キナーゼ１（ｈｐｋ１）阻害剤としてのインダゾールおよびその使用方法
KR102560178B1 (ko) * 2021-02-10 2023-07-27 재단법인 대구경북첨단의료산업진흥재단 이미다조[1,5-a]피라진 유도체 화합물 및 이를 유효성분으로 함유하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN113480543B (zh) * 2021-07-07 2022-05-17 无锡市第二人民医院 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
KR20250004665A (ko) * 2022-03-14 2025-01-08 퍼듀 리서치 파운데이션 비장 티로신 키나아제 억제제, 조성물 및 사용 방법
WO2023180976A1 (en) * 2022-03-25 2023-09-28 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods for using same
CN119630668A (zh) * 2022-07-25 2025-03-14 细胞基因公司 取代的咪唑并吡嗪化合物作为irak3结合剂
WO2024102970A1 (en) * 2022-11-11 2024-05-16 Kronos Bio, Inc. Compounds for modulating syk activity and e3 ubiquitin ligase activity

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4327027A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4337609A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
FR2723373B1 (fr) 1994-08-02 1996-09-13 Rhone Poulenc Rorer Sa Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6249495B1 (en) 1997-02-27 2001-06-19 Matsushita Electric Industrial Co., Ltd. Stepping motor control method and disk drive apparatus
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
AU2001275076A1 (en) 2000-06-19 2002-01-02 Armin S. Tay Axial position changing transmission mechanism
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2001297846A1 (en) 2000-11-20 2002-12-23 Cryoco, Inc. A method and apparatus for the preparation and usage of a cryogenic propellant or explosive system
DK174233B1 (da) 2000-12-27 2002-10-07 Dss Danish Separation Systems Sanitært spiralfilteranlæg
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7003125B2 (en) 2001-09-12 2006-02-21 Seung-Hwan Yi Micromachined piezoelectric microspeaker and fabricating method thereof
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
KR20050008691A (ko) * 2002-04-19 2005-01-21 셀룰러 지노믹스 아이엔씨 이미다조[1,2-ａ]피라진-8-일 아민, 그의 제조방법 및사용방법
US20040072081A1 (en) 2002-05-14 2004-04-15 Coleman Thomas P. Methods for etching photolithographic reticles
US7288075B2 (en) 2002-06-27 2007-10-30 Ethicon, Inc. Methods and devices utilizing rheological materials
JP2004053714A (ja) 2002-07-17 2004-02-19 Fuji Xerox Co Ltd 画像定着装置及び画像定着方法
US20040026867A1 (en) 2002-08-09 2004-02-12 Adams David J. Bearing seal
US6761361B2 (en) 2002-08-09 2004-07-13 Credo Technology Corporation Drill and drive apparatus with improved tool holder
US7312341B2 (en) * 2002-09-09 2007-12-25 Cgi Pharmaceuticals, Inc. 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
WO2004026867A2 (en) 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
KR20050057520A (ko) 2002-09-23 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피라진
CA2499874A1 (en) * 2002-09-23 2004-04-01 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
JP4056346B2 (ja) 2002-09-30 2008-03-05 三洋電機株式会社 非水電解質二次電池
EP2823820B1 (en) 2002-10-29 2018-06-06 Insmed Incorporated Liposomes comprising an aminoglycoside for the treatment of pulmonary infections
US7160885B2 (en) * 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
AR043002A1 (es) * 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7456393B2 (en) 2003-04-10 2008-11-25 Ge Homeland Protection, Inc. Device for testing surfaces of articles for traces of explosives and/or drugs
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) * 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
US7236749B2 (en) 2003-10-15 2007-06-26 Honeywell International Inc. Stuck microphone deselection system and method
WO2005047290A2 (en) * 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
JP2006099930A (ja) 2004-09-01 2006-04-13 Tdk Corp 情報記録媒体、記録再生装置およびスタンパー
US8145601B2 (en) 2004-09-09 2012-03-27 Microsoft Corporation Method, system, and apparatus for providing resilient data transfer in a data protection system
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2008519843A (ja) * 2004-11-10 2008-06-12 シージーアイ ファーマスーティカル インコーポレーテッド 特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
CN101124227A (zh) * 2004-11-10 2008-02-13 Cgi制药有限公司 可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺
JP4883959B2 (ja) 2005-08-17 2012-02-22 Ｎｔｎ株式会社 回転検出装置および回転検出装置付き軸受
GB0520838D0 (en) * 2005-10-13 2005-11-23 Glaxo Group Ltd Novel compounds
AU2006315718B2 (en) * 2005-11-10 2012-10-04 Merck Sharp & Dohme Corp. Imidazopyrazines as protein kinase inhibitors
JP4837378B2 (ja) 2006-01-04 2011-12-14 株式会社日立製作所 データの改竄を防止する記憶装置
US7446352B2 (en) 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
DE102006032495A1 (de) 2006-07-13 2008-02-07 Nokia Siemens Networks Gmbh & Co.Kg Verfahren und Vorrichtung zur Vermeidung von Interferenzen in einem zellulären Funkkommunikationssystem
US20080025821A1 (en) 2006-07-25 2008-01-31 Applied Materials, Inc. Octagon transfer chamber
BRPI0716239A2 (pt) 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
US8133895B2 (en) * 2007-05-10 2012-03-13 Janssen Pharmaceutica N.V. Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
ES2462642T3 (es) 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
WO2009102468A1 (en) * 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
ES2554615T3 (es) * 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
JP5318952B2 (ja) 2008-07-15 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー 新規なフェニル−イミダゾピリジン類及びピリダジン類
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
KR101745732B1 (ko) 2008-12-08 2017-06-12 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
AU2009325133B2 (en) 2008-12-08 2016-02-04 Gilead Connecticut, Inc. Imidazopyrazine Syk inhibitors
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US20110099133A1 (en) 2009-10-28 2011-04-28 Industrial Technology Research Institute Systems and methods for capturing and managing collective social intelligence information
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
JP5554746B2 (ja) 2011-05-06 2014-07-23 株式会社日立製作所 ガス絶縁母線及びガス絶縁母線の異物除去方法
US20140148430A1 (en) 2012-11-26 2014-05-29 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors

Also Published As

Publication number Publication date
HRP20161036T1 (hr) 2017-06-16
JP2014139251A (ja) 2014-07-31
JP2012510997A (ja) 2012-05-17
EP2716157B1 (en) 2016-05-18
HK1162250A1 (en) 2012-08-31
VN28228A1 (en) 2011-12-26
IL213365A0 (en) 2011-07-31
US9120811B2 (en) 2015-09-01
IL213365A (en) 2014-11-30
DK2716157T3 (en) 2016-08-15
US8748607B2 (en) 2014-06-10
HK1211939A1 (en) 2016-06-03
PL2716157T3 (pl) 2017-06-30
SG171991A1 (en) 2011-07-28
LT2716157T (lt) 2016-09-12
BRPI0922225A2 (pt) 2020-10-06
JP5567587B2 (ja) 2014-08-06
MX2011006091A (es) 2011-11-29
US20140357627A1 (en) 2014-12-04
EA020461B1 (ru) 2014-11-28
JP2017101090A (ja) 2017-06-08
NZ593459A (en) 2013-09-27
US20130237521A1 (en) 2013-09-12
KR20150004436A (ko) 2015-01-12
US9212191B2 (en) 2015-12-15
CN102307474B (zh) 2015-04-01
TW201033212A (en) 2010-09-16
PT2373169E (pt) 2015-10-05
US20130237520A1 (en) 2013-09-12
US9796718B2 (en) 2017-10-24
WO2010068257A1 (en) 2010-06-17
CY1118377T1 (el) 2017-06-28
EA201690111A1 (ru) 2017-01-30
SI2373169T1 (sl) 2015-10-30
SI2716157T1 (sl) 2016-10-28
PT2716157T (pt) 2016-08-23
HUE030427T2 (en) 2017-05-29
TWI478922B (zh) 2015-04-01
CA2746023A1 (en) 2010-06-17
JP2015205935A (ja) 2015-11-19
IL234326A (en) 2017-09-28
JP6132445B2 (ja) 2017-05-24
US20100222323A1 (en) 2010-09-02
AU2009325132B2 (en) 2016-03-17
KR101745732B1 (ko) 2017-06-12
KR20170013414A (ko) 2017-02-06
AU2009325132A1 (en) 2011-06-30
EP2716157A1 (en) 2014-04-09
US8765761B2 (en) 2014-07-01
US20140336169A1 (en) 2014-11-13
EP3123864A1 (en) 2017-02-01
US20160031894A1 (en) 2016-02-04
TW201529576A (zh) 2015-08-01
US8455493B2 (en) 2013-06-04
PL2373169T3 (pl) 2015-10-30
PE20140975A1 (es) 2014-08-25
TWI529172B (zh) 2016-04-11
HK1196037A1 (en) 2014-12-05
CN104744476A (zh) 2015-07-01
EA024140B1 (ru) 2016-08-31
EA201190042A1 (ru) 2012-02-28
KR101748925B1 (ko) 2017-06-19
KR20110098795A (ko) 2011-09-01
KR20170066685A (ko) 2017-06-14
ES2545610T3 (es) 2015-09-14
CN104744476B (zh) 2017-04-12
US20180086769A1 (en) 2018-03-29
CN102307474A (zh) 2012-01-04
EP2373169A1 (en) 2011-10-12
ES2590804T3 (es) 2016-11-23
CO6390078A2 (es) 2012-02-29
EA201400197A1 (ru) 2014-09-30
CL2011001360A1 (es) 2012-03-16
RS55055B1 (sr) 2016-12-30
SMT201600267B (it) 2016-08-31
CA2746023C (en) 2018-03-27
EP2373169B1 (en) 2015-05-20
EP2373169A4 (en) 2012-08-29
JP5832586B2 (ja) 2015-12-16
BRPI0922225B1 (pt) 2022-01-11
IL235837A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20080524A1 (es) DERIVADOS DE 1H-IMIDAZO[4,5-b]PIRAZIN Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
PE20090904A1 (es) ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b
CO6290658A2 (es) Derivados de azetidina y ciclobutano como inhibidores de jack
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20091493A1 (es) Inhibidores de quinasa de pirrolopirazina
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
EA201070422A1 (ru) Производные оксадиазола
PE20110991A1 (es) Compuestos de fenil-piridazinona-pirazol-fenilo como inhibidores de pde
CR9929A (es) Nuevos compuestos
PE20090674A1 (es) Compuestos multiciclicos
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
SMP201100019B (it) Composti organici
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
PE20070517A1 (es) Derivados de imidazol como agentes inhibidores de la sintasa de aldosterona y aromatasa
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas

Legal Events

Date Code Title Description
FG Grant, registration